
Growth requires financing as Exiqon takes the last crucial steps towards becoming a profitable and self-sustaining business, CEO Lars Kongsbak tells Medwatch following a decision from the company to issue corporate bonds to a small group of investors, which has given the company 15 milion kroner (USD 2.6 million).
“It is primarily in order to finance growth. The numbers are so big in Exiqon now that we need a bigger working capital tied up in inventory and receivables,” he explains.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app